G-protein-coupled receptor regulators and methods of use thereof
US-2024417378-A1 · Dec 19, 2024 · US
US11840537B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11840537-B2 |
| Application number | US-202117488317-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 29, 2021 |
| Priority date | Nov 3, 2020 |
| Publication date | Dec 12, 2023 |
| Grant date | Dec 12, 2023 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A 5-bromoquinazoline derivative (I), structural formula thereof is as follows: the synthesis method thereof comprises weighing 1.18 g of 5-bromoisatin, 2.5503 g of ammonium formate and 100 ml of absolute methanol in a 250 mL round-bottom flask, heating, stirring and refluxing for 48 h, stopping reaction, rotating to obtain 1.6033 g of filter residue crude product, carrying out column chromatography separation by using dichloromethane and absolute methanol according to a volume ratio of 1:1, and obtaining a target crystal compound I; the application of the 5-bromoquinazoline derivative compound crystal (I), as a catalyst has a good catalytic effect in nitrile silicification reaction of benzaldehyde and auto-polymerization reaction of benzophenone hydrazone, the conversion rates thereof respectively reach 39% and 76%, and the crystal (I) can be used as an anti-cancer reagent which has certain anti-cancer activity of breast cancer, liver cancer and lung cancer.
Opening claim text (preview).
The invention claimed is: 1. A 5-bromoquinazoline derivative (I), structural formula thereof is as follows: 2. The 5-bromoquinazoline derivative crystal (I) of claim 1 , at the temperature of 293(2) K, and on the Oxford X-ray single crystal diffractometer, diffraction data is collected by w-O scanning mode with MoKα rays (λ=0.71073 Å) monochromatized by a graphite monochromator, wherein the crystal belongs to the triclinic system, P-1, cell parameters: a=8.7881(5) Å alpha=98.254(2)deg; b=9.9375(5) Å beta=97.014(2)deg; c=17.8389(9) Å gamma=112.154deg. 3. A synthesis method of the 5-bromoquinazoline derivative compound (I) of claim 1 , comprising heating 5-bromoisatin and ammonium formate in absolute methanol to obtain the final product. 4. A method of synthesizing benzyloxy-trimethylsilane, comprising reacting benzaldehyde and TMSCN with a catalyst of formula (I) according to claim 1 in THF at room temperature to obtain the product. 5. A method of synthesizing 1,2-bis(diphenylmethylene)hydrazine, comprising heating a reaction of benzophenone hydrazone with a catalyst of formula (I) according to claim 1 in methanol to obtain the product.
Spiro-condensed systems · CPC title
of ether, acetal or ketal groups · CPC title
Crystalline forms, e.g. polymorphs · CPC title
Antineoplastic agents · CPC title
also containing elements or functional groups covered by B01J31/0201 - B01J31/0231 · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.